Detailseite
Projekt Druckansicht

Die Rolle des Zytokins GM-CSF in der Modulation der Antitumor-Immunität bei myeloproliferativen Neoplasien.

Antragsteller Dr. Tobias Wertheimer
Fachliche Zuordnung Hämatologie, Onkologie
Immunologie
Förderung Förderung von 2021 bis 2025
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 463384799
 
Erstellungsjahr 2024

Zusammenfassung der Projektergebnisse

The initial proposal aimed to elucidate the contribution of the cytokine GM-CSF as a communication signal between T cells and myeloid cells in the tumor microenvironment of myeloproliferative diseases. Albeit preliminary data suggest no major influence on GM-CSF on the disease progression of MPN in a preclinical model, the research question could so far not be sufficiently and conclusively answered most importantly due to organizational delays. Therefore, I investigated the role of Interleukin-23 (IL-23), which is another proinflammatory cytokine governing crosstalk between myeloid cells and T cells. Surprisingly, it was found that IL- 23 in the context of the tumor microenvironment (TME) is sensed by a subset of tumorinfiltrating regulatory T cells (Treg cells) marked by the expression of the IL-23 receptor (IL23R) in the murine und human TME. This Treg cell population displayed a highly activated and suppressive phenotype. The use of multiple preclinical cancer models in combination with ablation of Il23r in Tregs revealed that they are responsible for the tumor-promoting effect of IL-23. Mechanistically, our data demonstrate that IL-23 sensing by Treg cells represents a crucial signal driving the maintenance and stabilization of effector Treg cells involving the transcription factor Foxp3. This not only shows an unexpected immunosuppressive property of an otherwise pro-inflammatory cytokine, but also identifies the IL-23/IL-23R axis as a novel means of eliciting anti-tumor immunity.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung